[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-stage-breast-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-stage-breast-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,69,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641101","risk-stratified-hypofractionated-radiotherapy-after-breast-conserving-surgery-for-early-breast-cancer-100641101",false,"NCT07657442","Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer","A Prospective Study of Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer","Inclusion Criteria:\n\n* ECOG performance status score of 0 to 2.\n* Pathologically confirmed breast cancer, including invasive carcinoma or ductal carcinoma in situ.\n* Clinical stage cT0-2N0M0.\n* Underwent breast-conserving surgery.\n* Negative surgical margins greater than 2 mm.\n\nExclusion Criteria:\n\n* Regional lymph node metastasis.\n* Distant metastasis.\n* Bilateral breast cancer.\n* Prior thoracic radiotherapy.\n* Life expectancy of less than 5 years.\n* Lactating or pregnant women.","FEMALE","18 Years","75 Years",{"count":20,"type":21},649,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective study is designed to evaluate the feasibility, efficacy, and safety of risk-stratified hypofractionated radiotherapy after breast-conserving surgery in patients with early breast cancer.",[27,28],"Early Stage Breast Carcinoma","Breast Cancer",[30,31],"breast cancer","radiotherapy","NOT_YET_RECRUITING","2026-06-14",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":21},"2026-06-15",{"date":40,"type":21},"2032-12-31",{"name":42,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100622655","inspiratory-muscle-training-for-breast-cancer-patients-on-chemotherapy-100622655","NCT07386444","Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy","Effects of Inspiratory Muscle Training Among Breast Cancer Patients Undergoing Active Treatment (IMACT)","IMACT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Within 3 weeks of starting chemotherapy for an early-stage breast cancer diagnosis\n* Able to exercise independently without needing support\n* Ability to read, speak, understand English\n\nExclusion Criteria:\n\n* Metastatic breast cancer\n* Unwilling or unable to follow protocol requirements\n* Any significant health condition which in the investigator's opinion increases the risks of participation or makes the participant unsuitable for the study",{"count":54,"type":21},58,[24],"This clinical trial studies whether breathing exercises for the muscles that help with breathing air in, inspiratory muscle training (IMT), works to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage breast cancer (BC). Cancer and\u002For treatments for BC can directly result in muscle wasting that involves breathing muscles, skeletal muscles or heart muscles. Pain, weakness, shortness of breath, and side effects of cancer treatment may lead to lower physical activity levels. IMT involves breathing exercises using a small hand-held device. The device makes it a little harder to breathe in, which may help strengthen breathing muscles. IMT may be an effective way to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage BC.",[27,58],"Dyspnea","RECRUITING","2026-04-01",{"date":62,"type":36},"2026-04-06",{"date":64,"type":36},"2026-02-16",{"date":66,"type":21},"2026-12-31",{"name":68,"class":43},"Ohio State University Comprehensive Cancer Center",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100471360","evaluating-the-association-among-changes-in-gut-microbiome-fatigue-and-chemotherapy-induced-nausea-in-early-stage-breast-cancer-100471360","NCT05417867","Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer","Associations of Fatigue and Chemotherapy-Induced Nausea With Changes in Gut Microbiome Composition Profiles","Inclusion Criteria:\n\n* Subjects with a diagnosis of early stage breast cancer planning to receive moderate to highly emetogenic chemotherapy will be recruited at Mayo Clinic Health Systems including Mankato and Albert Lea; Mayo Clinic Arizona; Mayo Clinic Rochester (Minnesota); and Mayo Clinic Florida\n* At least 20 years of age\n* Last chemotherapy more than 3 years ago\n* Scheduled to receive moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies\n\nExclusion Criteria:\n\n* Metastatic disease\n* Concurrent radiation therapy\n* Concurrent antibiotic treatment","ALL","20 Years",{"count":79,"type":21},70,"OBSERVATIONAL","This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for early stage breast cancer. Patients undergoing chemotherapy may experience fatigue or nausea as a result of their treatment. Known risk factors for fatigue and CIN do not explain the differences in fatigue and CIN occurrence between patients, but changes in the functions of the gut microbiome may be related to the occurrence of fatigue and CIN. This study collects stool samples from breast cancer patients before and after chemotherapy to evaluate how changes in the microbiome may be associated with fatigue and CIN.",[83,27,84,85],"Chemotherapy-Related Nausea and\u002For Vomiting","Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","2026-03-26",{"date":88,"type":36},"2026-03-31",{"date":90,"type":36},"2021-04-14",{"date":92,"type":21},"2027-03-31",{"name":94,"class":43},"Mayo Clinic",5,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100524767","phase-2-prevention-of-frailty-with-fisetin-and-exercise-in-breast-cancer-survivors-100524767","NCT06113016","Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors","A Phase II Randomized Placebo-Controlled Study of Fisetin and Exercise to Prevent Frailty in Breast Cancer Survivors","PROFFi","Inclusion Criteria:\n\n* Women who are postmenopausal at the start of study treatment\n\n  * Postmenopausal status will be established as follows: Women who are 50 years or older and who are not menstruating for greater than 12 months will be considered postmenopausal. Women who are less than 50 years with an intact uterus and ovaries must have chemically induced menopause (e.g., ovarian suppression) to be considered postmenopausal\n* Women with a diagnosis of early-stage breast cancer (stage I, II, III) treated with neo\u002Fadjuvant chemotherapy within 12 months of starting study treatment\n* No evidence of active\u002Frecurrent breast cancer or other serious chronic illnesses\n* Have evidence of pre-frail health, defined as a 6-minute walk distance (400-480m) at baseline\n* Platelets \\> 60,000\u002Fmm\\^3\n* White blood cell count \\> 2,000\u002Fmm\\^3\n* Absolute neutrophil count \\> 500\u002Fmm\\^3\n* Hemoglobin ≥ 8.0 g\u002FdL\n* Total bilirubin ≤ 3.0 X upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) ≤ 4.0 x ULN\n* Alanine aminotransferase (ALT) ≤ 4.0 x ULN\n* Estimated glomerular filtration rate (eGFR) of ≥ 30mL\u002Fmin\u002F1.73m\\^2 per the Modification of Diet in Renal Disease (MDRD) calculation. GFR (mL\u002Fmin\u002F1.73 m²) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African American)\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Cancer-directed chemotherapy, biological therapy, or immunotherapy within 30 days prior to the start of study treatment. Exceptions include: trastuzumab, pertuzumab, pembrolizumab, tamoxifen, and aromatase inhibitors\n* Surgery and\u002For radiation within the last 30 days of starting study treatment (Exception: invasive non-major procedures such as an outpatient biopsy)\n* Subjects taking medications that are considered prohibited\n\n  * Exception: Subjects taking any of the medications under \"Temporary medication adjustment required\" may participate if they are otherwise eligible AND the medication can be safely withheld (from immediately before the 1st study agent administration until at least 10 hours after the last study agent administration, for each dosing interval)\n* On herbal and natural medications with possible senolytic properties (i.e., curcumin, kava kava, St. John's wort) and are unable or unwilling to hold its administration 2 days prior to and during study treatment dosing. Exceptions include cannabidiol (CBD), vitamins, probiotics, and fish oil. Other herbal and natural medications may be permitted or prohibited per clinician discretion\n* Subjects taking potentially senolytic agents within the last year: fisetin, quercetin, luteolin, dasatinib or imatinib (or other tyrosine kinase inhibitors), piperlongumine, or navitoclax\n* Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)\n* Issues with tolerating oral medication (such as but not limited to, inability to swallow pills (gastrostomy \\[g\\]-tubes not allowed), malabsorption issues, ongoing nausea or vomiting during screening, history of Crohn's, gastric bypass\u002Freduction, or celiac disease)\n* Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion\u002Ffatigue, or cognitive function",{"count":105,"type":21},164,[107],"PHASE2","This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity.",[110,85,111,27],"Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8","Anatomic Stage III Breast Cancer AJCC v8","2025-07-02",{"date":114,"type":36},"2025-07-08",{"date":116,"type":36},"2024-07-23",{"date":118,"type":21},"2028-12-30",{"name":120,"class":43},"Jonsson Comprehensive Cancer Center",6]